Image de couverture de livre

Impact of Dose‐Escalation Design on the Safety and Development of Anticancer Drugs in Clinical Trials

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Atsushi Nonami, Kensuke Matsuda, Kouta Funakoshi, Ryosuke Kato, Hideaki Takahashi, Yoko Edahiro
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Clinical and Translational Science
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Navigating Drug–Drug Interactions in Clinical Drug Development: A Tutorial
par: Jesmin Lohy Das, et autres
Publié: (2025)

High‐Frequency, At‐Home Monitoring of Drug Safety and Tolerability in Clinical Trials: Results From Studies of Fluvoxamine for COVID ‐19 Treatment
par: Eric J. Lenze, et autres
Publié: (2025)

Surfing the T Wave: A Primer on ECG T Wave Morphologies Encountered in Clinical Trials and Impact on the QT Interval and Patient Safety
par: Robert M. Lester, et autres
Publié: (2025)

Surrogate Endpoints in Pivotal Clinical Trials for Drug Approval in Japan Compared to the United States
par: Yuko Yamamoto, et autres
Publié: (2025)

Modulating Placebo Effects in Clinical Trials: Study Team Briefing to Optimize Drug–Placebo Differences
par: Martin Coenen, et autres
Publié: (2025)

Association of Protocol Design‐Related Factors With Enrollment Duration in Clinical Trials
par: Hiroaki Tsuchiya, et autres
Publié: (2026)

Clinical Evaluation of Drug–Drug Interactions With Aficamten
par: Neha Maharao, et autres
Publié: (2026)

Development and Validation of an Approach to Assessing Clinical Relevance of Potential Drug–Drug Interactions Inducing Rare but Serious Adverse Events
par: Menghuan Song, et autres
Publié: (2025)

New Function for Safety Signal Monitoring in MID‐NET®: The Case of an Anti‐COVID‐19 Drug
par: Yusuke Okada, et autres
Publié: (2025)

Clinical Pharmacology and Translational Science Considerations in the Development of Dual‐Payload Antibody Drug Conjugates
par: Paulien Ravenstijn, et autres
Publié: (2026)

Unlocking the Mysteries of Rare Disease Drug Development: A Beginner's Guide for Clinical Pharmacologists
par: Mariam A. Ahmed, et autres
Publié: (2025)

Clinical Significance of Drug–Drug Interaction Studies During Therapeutic Peptide Drug Development: Follow‐Up Investigation of Therapeutic Peptides Approved Between 2021 and 2024
par: Carolina Säll, et autres
Publié: (2025)

Informing Dose for Pediatric Rare Diseases—A Survey of Recent Orphan Drugs Approvals
par: Elimika Pfuma Fletcher, et autres
Publié: (2026)

Inter‐Ethnic Differences in the Efficacy and Safety of Tyrosine Kinase Inhibitors Used in Oncology: Insights From Phase 3 Clinical Trials
par: Nicki M. Kyriacou, et autres
Publié: (2025)

New Horizon in Clinical Development Strategy in Japan Based on New Guideline on Japanese Phase 1 Studies Prior to Multi‐Regional Clinical Trials
par: Kei Fukuhara, et autres
Publié: (2025)

Representation of Older Adult Patients in Clinical Trials
par: Sebastian Haertter, et autres
Publié: (2025)

Model‐Informed Optimal Dosing of Anti‐CD47 Antibody Using Target‐Mediated Drug Disposition Model
par: Seongmee Jeong, et autres
Publié: (2025)

Safety, Tolerability, and Pharmacokinetics of NIM‐1324 an Oral LANCL2 Agonist in a Randomized, Double‐Blind, Placebo‐Controlled Phase I Clinical Trial
par: Andrew Leber, et autres
Publié: (2025)

Use of Biomarkers in Drug Development for Regulatory Purposes
par: Robert N. Schuck, et autres
Publié: (2025)

From Models to Medicines: A Narrative History and Regulatory Perspective on the Translational Impact of Model‐Informed Drug Development ( MIDD )
par: Issam Zineh
Publié: (2026)

The Role of Candidate Polymorphisms in Drug Transporter Genes on High‐Dose Methotrexate in the Consolidation Phase of the AIEOP‐BFM ALL 2009 Protocol
par: Stefania Braidotti, et autres
Publié: (2025)

Pharmacokinetics and Safety of Fixed‐Dose Versus Separate Enavogliflozin/Gemigliptin Combinations, and Food Effect on Enavogliflozin in Healthy Korean Subjects
par: Young‐Sim Choi, et autres
Publié: (2025)

Strengthening the Food and Drug Administration Office of Clinical Pharmacology's Labeling Authority
par: Mark J. Ratain, et autres
Publié: (2025)

Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open‐Label, Fixed Sequence, Phase 1 Study
par: Jixiang Zhu, et autres
Publié: (2026)

Decentralized Clinical Trials in the Era of Real‐World Evidence: A Statistical Perspective
par: Jie Chen, et autres
Publié: (2025)

Exploration of Using an Open‐Source Large Language Model for Analyzing Trial Information: A Case Study of Clinical Trials With Decentralized Elements
par: Ki Young Huh, et autres
Publié: (2025)

Understanding Motivation to Participate in Clinical Trials: Insights to Diversify Clinical Research Using Health Information National Trends Survey
par: Rifath Ara Alam Barsha, et autres
Publié: (2026)

From Precision to Personalized: Catalyzing AI ‐Enabled Innovation in Drug Development
par: Adarsh Subbaswamy, et autres
Publié: (2026)

Optimizing Oligonucleotide Therapeutics: A Model‐Informed Drug Development Perspective
par: Ye Yuan, et autres
Publié: (2026)

Positioning Community Pharmacies in Nigeria as a Clinical Trial Partner: A Forward Perspective
par: Adeboye O. Bamgboye, et autres
Publié: (2026)

When Selectivity Increases Uncertainty: Context‐Dependent Pharmacology in Antibody Drug Development
par: Xiaozhi Liao, et autres
Publié: (2026)

Clinical Pharmaceutical Care in Nursing Home Residents as a Cornerstone for Drug‐Related Problems Identification
par: Milada Halačová, et autres
Publié: (2025)

Decentralized Clinical Trials in the Era of Real‐World Evidence: A Critical Assessment of Recent Experiences
par: Hongwei Wang, et autres
Publié: (2025)

Retrospective Analysis of Master Protocols in Tumor‐Agnostic Drug Development: Evaluation of Application to Single‐Agent Therapies With ORR as the Endpoint for Approval of Oncology Drugs
par: Keiko Yamamoto, et autres
Publié: (2025)

Integrating Sustainability Pillars Into Trial Design Decision‐Making: Results of an International Survey
par: Pritibha Singh, et autres
Publié: (2025)

Tutorial Drug–Drug Interactions
par: Edward M. Sellers
Publié: (2025)

Cross‐Reactive NSAID Hypersensitivity: Clinical Findings From Aspirin Provocation and Alternative Drug Challenge Testing
par: Young‐Il Koh, et autres
Publié: (2025)

From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry
par: Wonseok Yang, et autres
Publié: (2025)

Predictors of Clinical Trial Participation Among Older U.S. Adults With Multimorbidity: A Cross‐Sectional Survey
par: Janice B. Schwartz, et autres
Publié: (2026)

Insights From a User Experience‐Focused Virtual Study on the Feasibility and Challenges of Decentralized Clinical Trials
par: Yue Ma, et autres
Publié: (2025)